The Biotech Stock Research, LLC team has 18 dev-stage biotech companies under formal coverage. We are independent, with no bankers, no trading desk, we don't run a fund, and we're not paid by the companies we cover. See why PMs of funds with billions in assets make our research a regular read.
This is the yearly bible for BSR subscribers. We take every company in our coverage universe, refresh our analysis within a single month, grill management teams on their timeline projections and goals for the coming year, and wrap it all up in one big issue - 182 pages in 2009. It's available for single issue purchase.
